Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

Vanda Pharmaceuticals

Status and phase: Enrolling; Phase 2

Conditions: Hypertension; Uncontrolled Hypertension

Treatments: Drug: Placebo; Drug: iloperidone

Study type: Interventional

Funder types: Industry

Identifiers

NCT07090161

VP-VYV-683-2401

Details and patient eligibility

About

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension

Enrollment: 240 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• SiSBP >/= 130 mmHg despite >8 weeks treatment w/ 1 or more antihypertensive therapies

Exclusion criteria

• Confirmed Grade 3/severe hypertension (SiSBP >/= 180 mmHg, SiDBP >/= 120 mmHg), unstable cardiac disease, renal insufficiency

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

240 participants in 2 patient groups, including a placebo group

Experimental/Iloperidone

Experimental group

Treatment:

Drug: iloperidone

Placebo Comparator

Placebo Comparator group

Treatment:

Drug: Placebo